• Lung Cancer Group Cologne
  • Contact
  • Privacy Policy
  • English
    • Deutsch (German)
Netzwerk Genomische Medizin Lungenkrebs
  • Home
  • Health insurance companies
  • General information
  • Privacy Policy
  • Cookie Policy
  • Diagnostics
  • Hybrid-capture
  • Driver mutations
  • Fast-track analysis for first-line treatment
  • Driver mutations in lung cancer
  • Network Genomic Medicine – Lung Cancer
  • New therapeutic approaches from genomic research
  • New immunotherapeutic therapeutic approaches
  • Molecular Diagnostics
  • Contact
  • Imprint
  • Second Opinion service
  • Service invoicing
    • For pathologists
  • Map
  • Clinical trials
    • General information
    • Lung Cancer Study Group
    • What is a clinical trial?
    • Participation in a trial
  • The Network
    • Aims
    • Funding
    • Network Genomic Medicine cancer information system (NGMcis)
    • Publications
    • Related links
    • Our team
  • Ärzte
  • Veranstaltungen
Select Page

Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients

Plenker D, Bertrand M, de Langen AJ, Riedel R, Lorenz C, Scheel AH, Müller J, Brägelmann J, Daßler-Plenker J, Kobe C, Persigehl T, Kluge A, Wurdinger T, Schellen P, Hartmann G, Zacherle T, Menon R, Thunnissen E, Büttner R, Griesinger F, Wolf J, Heukamp L, Sos ML, Heuckmann JM

Journal: Clinical Cancer Research
published: 2018 Mar 15

  • © 2016-2018 Network Genomic Medicine (NGM)
  • Contact
  • Imprint
  • Privacy Policy

Designed by Elegant Themes | Powered by WordPress